Susanna C Larsson1, Andrew B Singleton2, Mike A Nalls2,3, J Brent Richards4. 1. Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA. 3. Data Tecnica International, Glen Echo, Maryland, USA. 4. Centre for Clinical Epidemiology, Departments of Medicine, Genetics and Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec, Canada.
Abstract
BACKGROUND: Observational studies have found that relative to healthy controls, patients with Parkinson's disease have lower circulating concentrations of 25-hydroxyvitamin D, a clinical biomarker of vitamin D status. However, the causality of this association is uncertain. We undertook a Mendelian randomization study to investigate whether genetically decreased 25-hydroxyvitamin D concentrations are associated with PD to minimize confounding and prevent bias because of reverse causation. METHODS: As instrumental variables for the Mendelian randomization analysis, we used 4 single-nucleotide polymorphisms that affect 25-hydroxyvitamin D concentrations (rs2282679 in GC, rs12785878 near DHCR7, rs10741657 near CYP2R1, and rs6013897 near CYP24A1). Summary effect size estimates of the 4 single-nucleotide polymorphisms on PD were obtained from the International Parkinson's Disease Genomics Consortium (including 5333 PD cases and 12,019 controls). The estimates of the 4 single-nucleotide polymorphisms were combined using an inverse-variance weighted meta-analysis. RESULTS: Of the 4 single-nucleotide polymorphisms associated with 25-hydroxyvitamin D concentrations, one (rs6013897 in CYP24A1) was associated with PD (odds ratio per 25-hydroxyvitamin D-decreasing allele, 1.09; 95% confidence interval, 1.02-1.16; P = 0.008), whereas no association was observed with the other 3 single-nucleotide polymorphisms (P > 0.23). The odds ratio of PD per genetically predicted 10% lower 25-hydroxyvitamin D concentration, based on the 4 single-nucleotide polymorphisms, was 0.98 (95% confidence interval, 0.93-1.04; P = 0.56). CONCLUSIONS: This Mendelian randomization study provides no clear support that lowered 25-hydroxyvitamin D concentration is causally associated with risk of PD.
RCT Entities:
BACKGROUND: Observational studies have found that relative to healthy controls, patients with Parkinson's disease have lower circulating concentrations of 25-hydroxyvitamin D, a clinical biomarker of vitamin D status. However, the causality of this association is uncertain. We undertook a Mendelian randomization study to investigate whether genetically decreased 25-hydroxyvitamin D concentrations are associated with PD to minimize confounding and prevent bias because of reverse causation. METHODS: As instrumental variables for the Mendelian randomization analysis, we used 4 single-nucleotide polymorphisms that affect 25-hydroxyvitamin D concentrations (rs2282679 in GC, rs12785878 near DHCR7, rs10741657 near CYP2R1, and rs6013897 near CYP24A1). Summary effect size estimates of the 4 single-nucleotide polymorphisms on PD were obtained from the International Parkinson's Disease Genomics Consortium (including 5333 PD cases and 12,019 controls). The estimates of the 4 single-nucleotide polymorphisms were combined using an inverse-variance weighted meta-analysis. RESULTS: Of the 4 single-nucleotide polymorphisms associated with 25-hydroxyvitamin D concentrations, one (rs6013897 in CYP24A1) was associated with PD (odds ratio per 25-hydroxyvitamin D-decreasing allele, 1.09; 95% confidence interval, 1.02-1.16; P = 0.008), whereas no association was observed with the other 3 single-nucleotide polymorphisms (P > 0.23). The odds ratio of PD per genetically predicted 10% lower 25-hydroxyvitamin D concentration, based on the 4 single-nucleotide polymorphisms, was 0.98 (95% confidence interval, 0.93-1.04; P = 0.56). CONCLUSIONS: This Mendelian randomization study provides no clear support that lowered 25-hydroxyvitamin D concentration is causally associated with risk of PD.
Authors: C Annweiler; E Dursun; F Féron; D Gezen-Ak; A V Kalueff; T Littlejohns; D J Llewellyn; P Millet; T Scott; K L Tucker; S Yilmazer; O Beauchet Journal: J Intern Med Date: 2014-07-19 Impact factor: 8.989
Authors: Zheng Ye; Stephen J Sharp; Stephen Burgess; Robert A Scott; Fumiaki Imamura; Claudia Langenberg; Nicholas J Wareham; Nita G Forouhi Journal: Lancet Diabetes Endocrinol Date: 2014-09-30 Impact factor: 32.069
Authors: Lisanne M Rimmelzwaan; Natasja M van Schoor; Paul Lips; Henk W Berendse; Elisabeth M W Eekhoff Journal: J Parkinsons Dis Date: 2016 Impact factor: 5.568
Authors: James R Staley; James Blackshaw; Mihir A Kamat; Steve Ellis; Praveen Surendran; Benjamin B Sun; Dirk S Paul; Daniel Freitag; Stephen Burgess; John Danesh; Robin Young; Adam S Butterworth Journal: Bioinformatics Date: 2016-06-17 Impact factor: 6.937
Authors: Karani S Vimaleswaran; Diane J Berry; Chen Lu; Emmi Tikkanen; Stefan Pilz; Linda T Hiraki; Jason D Cooper; Zari Dastani; Rui Li; Denise K Houston; Andrew R Wood; Karl Michaëlsson; Liesbeth Vandenput; Lina Zgaga; Laura M Yerges-Armstrong; Mark I McCarthy; Josée Dupuis; Marika Kaakinen; Marcus E Kleber; Karen Jameson; Nigel Arden; Olli Raitakari; Jorma Viikari; Kurt K Lohman; Luigi Ferrucci; Håkan Melhus; Erik Ingelsson; Liisa Byberg; Lars Lind; Mattias Lorentzon; Veikko Salomaa; Harry Campbell; Malcolm Dunlop; Braxton D Mitchell; Karl-Heinz Herzig; Anneli Pouta; Anna-Liisa Hartikainen; Elizabeth A Streeten; Evropi Theodoratou; Antti Jula; Nicholas J Wareham; Claes Ohlsson; Timothy M Frayling; Stephen B Kritchevsky; Timothy D Spector; J Brent Richards; Terho Lehtimäki; Willem H Ouwehand; Peter Kraft; Cyrus Cooper; Winfried März; Chris Power; Ruth J F Loos; Thomas J Wang; Marjo-Riitta Järvelin; John C Whittaker; Aroon D Hingorani; Elina Hyppönen Journal: PLoS Med Date: 2013-02-05 Impact factor: 11.069
Authors: Lauren E Mokry; Stephanie Ross; Omar S Ahmad; Vincenzo Forgetta; George Davey Smith; David Goltzman; Aaron Leong; Celia M T Greenwood; George Thanassoulis; J Brent Richards Journal: PLoS Med Date: 2015-08-25 Impact factor: 11.069
Authors: A F Bais; R M Lucas; J F Bornman; C E Williamson; B Sulzberger; A T Austin; S R Wilson; A L Andrady; G Bernhard; R L McKenzie; P J Aucamp; S Madronich; R E Neale; S Yazar; A R Young; F R de Gruijl; M Norval; Y Takizawa; P W Barnes; T M Robson; S A Robinson; C L Ballaré; S D Flint; P J Neale; S Hylander; K C Rose; S-Å Wängberg; D-P Häder; R C Worrest; R G Zepp; N D Paul; R M Cory; K R Solomon; J Longstreth; K K Pandey; H H Redhwi; A Torikai; A M Heikkilä Journal: Photochem Photobiol Sci Date: 2018-02-14 Impact factor: 3.982
Authors: Roger Bouillon; Claudio Marcocci; Geert Carmeliet; Daniel Bikle; John H White; Bess Dawson-Hughes; Paul Lips; Craig F Munns; Marise Lazaretti-Castro; Andrea Giustina; John Bilezikian Journal: Endocr Rev Date: 2019-08-01 Impact factor: 19.871
Authors: Ludmila A R Lima; Maria Janice P Lopes; Roberta O Costa; Francisco Arnaldo V Lima; Kelly Rose T Neves; Iana B F Calou; Geanne M Andrade; Glauce S B Viana Journal: J Neuroinflammation Date: 2018-08-31 Impact factor: 8.322